BPH Surgical Treatment Market

The BPH Surgical Treatment market is expected to grow from USD 12.62 billion in 2024 to USD 17.19 billion by 2030 at a growth rate of 5.3% CAGR. The BPH surgical treatment market is growing due to the rising prevalence of older men population and increasing cases of obesity, along with the increasing demand for minimally invasive surgery procedures for BPH Treatment. The favorable reimbursement policies, improved healthcare infrastructure, insurance coverage, and favorable reimbursement policies are the related driving factors for the market growth.

The  BPH Surgical Treatment market is consolidated, with top companies holding significant market shares. The top three players in the drug type market include GlaxoSmithKline PLC (UK) Astellas Pharma Inc. (Japan) and Viatris Inc. (US. Also, the top three players in the type market includes Teleflex Incorporated (US), Boston Scientific Corporation (US), and Olympus Corporation (Japan) dominating the market.

To know about the assumptions considered for the study download the pdf brochure

Players in this market are focusing on adopting organic and inorganic growth strategies such as product approvals, acquisitions, agreements, partnerships, and other developments such as regulatory approvals to increase their BPH treatment products portfolio, cater to customer needs, increase their profitability and expand their presence in the global BPH surgical treatment market.

By Drug Type-

Viatris Inc. (US) is the leading player contributing a share of  10-12% in 2023 in the BPH Surgical treatment market The company offers 1,400 approved molecules of various therapeutic areas which includes key brands and generics recognized globally. The brand division caters to the BPH surgical products market, i.e., Apha1 adrenergic antagonist known as CARDURA (doxazosin).

GlaxoSmithKline PLC (UK) is the second leading BPH surgical treatment market player, with a 6.0-8.0% share in 2023. The Commercial Operations segment has three product groups: Vaccines, Specialty Medicines, and General Medicines. The company offers various products to treat chronic & acute diseases. The products for BHP treatment are provided through its General Medicines product group under the Commercial Operations segment. The company offers 5-Alpha-Reductase Inhibitors by the brand name Avodart and a combination drug with dutasteride 500 µg and 400 µg tamsulosin hydrochloride by the brand name Duodart. In July 2023, GlaxoSmithKline PLC and Recordati entered into an agreement with GSK to commercialize Avodart (dutasteride) and Combodart/Duodart (dutasteride/tamsulosin) across 21 countries, mainly in Europe, excluding only those where GSK already has a distribution agreement in place.

Astellas Pharma Inc. (Japan) In the BPH surgical treatment market the company accounts for a share of around 4-6% in 2023. Pharmaceutical products are manufactured and marketed by a single business segment. Th key segments targeted are immunology, anti-infectives, oncology, urology, and metabolic applications. The company provides alpha blocker Harnal (Tamsulosin hydrochloride) for the treatment BPH  by the Urology category. The company have a global presence in around 40 countries across the world.

By Type-

Boston Scientific Corporation (US) is the leading BPH surgical treatment market player, with a share of 9.0-10.0% in 2023. The various procedures offered by the company include Greenlight XPS Laser System, Moxy Fiber, and Rezum Systems for treating BPH.

Teleflex Incorporated (US) is ranked as the second leading player in the BPH surgical treatment market. In 2023, The company is contributing a share of 8.0-9.0% in 2023. The Interventional Urology segment offers the UroLift System which is a minimally invasive technology benign prostatic hyperplasia. The company has also introduced the UroLift system in China to make notable progress in advancing other high-growth products and line extensions through the regulatory process.

Olympus Corporation (Japan) accounted for a share of 8.0% in 2023 in the BPH surgical treatment market. The underlying high-frequency technology of PLASMA has been used for over 17 years. It offers proven therapy for patients with benign prostatic hyperplasia (BPH) and expanded reimbursement for differentiated MIS BPH devices, which provide better clinical outcomes and elevate the standard of care.

Related Reports:

BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com